Loading...

Dennis Black, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentEpidemiology & Biostatistics
Address550 16th. Street
San Francisco CA 94158
Phone415-514-8159
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    UCSF Core Center for Musculoskeletal Biology and Medicine
    NIH/NIAMS P30AR066262Jul 1, 2014 - Jun 30, 2019
    Role: Co-Investigator
    Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center
    NIH U01HL094355Sep 15, 2009 - Jul 31, 2014
    Role: Principal Investigator
    PTH and ALDENRONATE COMBINATION TREATMENT OSTEOPOROSIS-264002245
    NIH N01AR002245Oct 27, 1999 - Oct 28, 2004
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical Femur Fractures - Review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocr Rev. 2018 Aug 29. PMID: 30169557.
      View in: PubMed
    2. Adams AL, Fischer H, Kopperdahl DL, Lee DC, Black DM, Bouxsein ML, Fatemi S, Khosla S, Orwoll ES, Siris ES, Keaveny TM. Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). J Bone Miner Res. 2018 Apr 17. PMID: 29665068.
      View in: PubMed
    3. Wai KC, Hibbs AM, Steurer MA, Black DM, Asselin JM, Eichenwald EC, Ballard PL, Ballard RA, Keller RL. Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. J Pediatr. 2018 Apr 04. PMID: 29627188.
      View in: PubMed
    4. Bauer DC, Black DM, Bouxsein ML, Lui LY, Cauley JA, de Papp AE, Grauer A, Khosla S, McCulloch CE, Eastell R. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res. 2018 Apr; 33(4):634-642. PMID: 29318649.
      View in: PubMed
    5. Napoli N, Schwartz AV, Black DM. Reply to: Indications of Increased Vertebral Fracture Risk in Patients With Type 2 Diabetes. J Bone Miner Res. 2018 Jan; 33(1):183. PMID: 29077237.
      View in: PubMed
    6. Napoli N, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, Black DM. Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. J Bone Miner Res. 2018 Jan; 33(1):63-69. PMID: 28861910.
      View in: PubMed
    7. Schafer AL, Kazakia GJ, Vittinghoff E, Stewart L, Rogers SJ, Kim TY, Carter JT, Posselt AM, Pasco C, Shoback DM, Black DM. Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. J Bone Miner Res. 2017 Dec 27. PMID: 29281126.
      View in: PubMed
    8. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med. 2017 Oct 01; 177(10):1471-1479. PMID: 28846767.
      View in: PubMed
    9. LeBlanc ES, Rosales AG, Black DM, Genant HK, Dell RM, Friess DM, Boardman DL, Bauer DC, de Papp A, Santora AC, Orwoll ES. Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting. J Bone Miner Res. 2017 Nov; 32(11):2304-2314. PMID: 28731209.
      View in: PubMed
    10. Kim TY, Schwartz AV, Li X, Xu K, Black DM, Petrenko DM, Stewart L, Rogers SJ, Posselt AM, Carter JT, Shoback DM, Schafer AL. Bone Marrow Fat Changes After Gastric Bypass Surgery Are Associated With Loss of Bone Mass. J Bone Miner Res. 2017 Nov; 32(11):2239-2247. PMID: 28791737.
      View in: PubMed
    11. Black DM, Cauley JA, Wagman R, Ensrud K, Fink HA, Hillier TA, Lui LY, Cummings SR, Schousboe JT, Napoli N. The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. J Bone Miner Res. 2018 Mar; 33(3):389-395. PMID: 28719727.
      View in: PubMed
    12. Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause. 2017 Mar; 24(3):238-246. PMID: 27779568.
      View in: PubMed
    13. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017 Feb; 92(2):200-210. PMID: 28160873.
      View in: PubMed
    14. Keller RL, Eichenwald EC, Hibbs AM, Rogers EE, Wai KC, Black DM, Ballard PL, Asselin JM, Truog WE, Merrill JD, Mammel MC, Steinhorn RH, Ryan RM, Durand DJ, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, Helderman J, Porta NF, Wadhawan R, Palermo L, Ballard RA. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. J Pediatr. 2017 Apr; 183:19-25.e2. PMID: 28100402.
      View in: PubMed
    15. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S. Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res. 2017 Jan; 32(1):3-10. PMID: 27864889.
      View in: PubMed
    16. Zhang AL, Sing DC, Dang DY, Ma CB, Black D, Vail TP, Feeley BT. Overlapping Surgery in the Ambulatory Orthopaedic Setting. J Bone Joint Surg Am. 2016 Nov 16; 98(22):1859-1867. PMID: 27852902.
      View in: PubMed
    17. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. J Bone Miner Res. 2017 Jan; 32(1):17-23. PMID: 27612281.
      View in: PubMed
    18. Cavalli L, Guazzini A, Cianferotti L, Parri S, Cavalli T, Metozzi A, Giusti F, Fossi C, Black DM, Brandi ML. Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign. BMC Musculoskelet Disord. 2016 09 17; 17(1):396. PMID: 27639376; PMCID: PMC5027125.
    19. Wai KC, Kohn MA, Ballard RA, Truog WE, Black DM, Asselin JM, Ballard PL, Rogers EE, Keller RL. Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. J Pediatr. 2016 Oct; 177:97-102.e2. PMID: 27470692; PMCID: PMC5037007 [Available on 10/01/17].
    20. Napoli N, Schafer AL, Lui LY, Cauley JA, Strotmeyer ES, Le Blanc ES, Hoffman AR, Lee CG, Black DM, Schwartz AV. Serum 25-hydroxyvitamin D level and incident type 2 diabetes in older men, the Osteoporotic Fractures in Men (MrOS) study. Bone. 2016 09; 90:181-4. PMID: 27393241.
      View in: PubMed
    21. Black DM, Rosen CJ. Postmenopausal Osteoporosis. N Engl J Med. 2016 05 26; 374(21):2096-7. PMID: 27223157.
      View in: PubMed
    22. Borggrefe J, de Buhr T, Shrestha S, Marshall LM, Orwoll E, Peters K, Black DM, Glüer CC. Association of 3D Geometric Measures Derived From Quantitative Computed Tomography With Hip Fracture Risk in Older Men. J Bone Miner Res. 2016 Aug; 31(8):1550-8. PMID: 26916713.
      View in: PubMed
    23. van de Glind EM, Willems HC, Eslami S, Abu-Hanna A, Lems WF, Hooft L, de Rooij SE, Black DM, van Munster BC. Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. Drugs Aging. 2016 May; 33(5):347-53. PMID: 26884390; PMCID: PMC4837200.
    24. Bell KJ, Hayen A, Glasziou P, Irwig L, Eastell R, Harrison SL, Black DM, Bauer DC. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. J Bone Miner Res. 2016 Sep; 31(9):1767-73. PMID: 27027655.
      View in: PubMed
    25. Ensrud KE, Blackwell TL, Fink HA, Zhang J, Cauley JA, Cawthon PM, Black DM, Bauer DC, Curtis JR, Orwoll ES, Barrett-Connor E, Kado DM, Marshall LM, Shikany JM, Schousboe JT. What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. J Bone Miner Res. 2016 Aug; 31(8):1500-3. PMID: 26969847.
      View in: PubMed
    26. Cummings SR, Kiel DP, Black DM. Vitamin D Supplementation and Increased Risk of Falling: A Cautionary Tale of Vitamin Supplements Retold. JAMA Intern Med. 2016 Feb; 176(2):171-2. PMID: 26746474.
      View in: PubMed
    27. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016 Jan 21; 374(3):254-62. PMID: 26789873.
      View in: PubMed
    28. Cawthon PM, Schousboe JT, Harrison SL, Ensrud KE, Black D, Cauley JA, Cummings SR, LeBlanc ES, Laughlin GA, Nielson CM, Broughton A, Kado DM, Hoffman AR, Jamal SA, Barrett-Connor E, Orwoll ES. Sex hormones, sex hormone binding globulin, and vertebral fractures in older men. Bone. 2016 Mar; 84:271-278. PMID: 26778261.
      View in: PubMed
    29. Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ, Lobo RA, Taylor HS, Manson JE, Black DM, Naftolin F, Harman SM, de Andrade M. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics. 2016 Jan; 48(1):33-41. PMID: 26508701; PMCID: PMC4757027 [Available on 01/01/17].
    30. Ballard RA, Keller RL, Black DM, Ballard PL, Merrill JD, Eichenwald EC, Truog WE, Mammel MC, Steinhorn RH, Rogers EE, Ryan RM, Durand DJ, Asselin JM, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, O'Shea TM, Porta NF, Wadhawan R, Palermo L. Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. J Pediatr. 2016 Jan; 168:23-9.e4. PMID: 26500107; PMCID: PMC4698022 [Available on 01/01/17].
    31. Ensrud KE, Blackwell TL, Cawthon PM, Bauer DC, Fink HA, Schousboe JT, Black DM, Orwoll ES, Kado DM, Cauley JA, Mackey DC. Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men Versus Older Women. J Bone Miner Res. 2016 Jan; 31(1):204-7. PMID: 26178795; PMCID: PMC4730881 [Available on 01/01/17].
    32. Treece GM, Gee AH, Tonkin C, Ewing SK, Cawthon PM, Black DM, Poole KE. Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. 2015 Nov; 30(11):2067-77. PMID: 25982802; PMCID: PMC4657505.
    33. Szulc P, Blackwell T, Kiel DP, Schousboe JT, Cauley J, Hillier T, Hochberg M, Rodondi N, Taylor BC, Black D, Cummings S, Ensrud KE. Abdominal aortic calcification and risk of fracture among older women - The SOF study. Bone. 2015 Dec; 81:16-23. PMID: 26115911.
      View in: PubMed
    34. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015 Jun; 12(6):e1001833; discussion e1001833. PMID: 26035291; PMCID: PMC4452757.
    35. Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, Stewart L, Rogers SJ, Carter JT, Posselt AM, Shoback DM, Sellmeyer DE. Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. J Bone Miner Res. 2015 Aug; 30(8):1377-85. PMID: 25640580; PMCID: PMC4593653.
    36. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015 May; 30(5):934-44. PMID: 25545380.
      View in: PubMed
    37. Eastell R, Boonen S, Cosman F, Reid IR, Palermo L, Cummings SR, Black DM. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. J Bone Miner Res. 2015 Mar; 30(3):570-4. PMID: 25214069.
      View in: PubMed
    38. Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, Barrett-Connor E, Marshall L, Steiger P, Schousboe JT. Response to BONE-D-14-00884. Bone. 2015 Jun; 75:246. PMID: 25481408.
      View in: PubMed
    39. Yang L, Palermo L, Black DM, Eastell R. Prediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures. J Bone Miner Res. 2014 Dec; 29(12):2594-600. PMID: 24898426; PMCID: PMC4388249.
    40. Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014 Dec; 99(12):4546-54. PMID: 25215556.
      View in: PubMed
    41. Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med. 2014 Oct; 174(10):1550-7. PMID: 25111880; PMCID: PMC4398333.
    42. Cawthon PM, Blackwell TL, Marshall LM, Fink HA, Kado DM, Ensrud KE, Cauley JA, Black D, Orwoll ES, Cummings SR, Schousboe JT. Physical performance and radiographic and clinical vertebral fractures in older men. J Bone Miner Res. 2014 Sep; 29(9):2101-8. PMID: 25042072; PMCID: PMC4335673.
    43. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014 Aug 19; 161(4):249-60. PMID: 25069991.
      View in: PubMed
    44. McNabb B, Vittinghoff E, Eastell R, Schwartz AV, Bauer DC, Ensrud K, Barrett-Connor E, Black DM. A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab. 2014 Nov; 99(11):4094-100. PMID: 25127011.
      View in: PubMed
    45. Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, Barrett-Connor E, Marshall L, Steiger P, Schousboe JT. Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in men study. Bone. 2014 Oct; 67:152-5. PMID: 25003811; PMCID: PMC4152008.
    46. Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014 Jul; 174(7):1126-34. PMID: 24798675; PMCID: PMC4409325.
    47. Ballard PL, Keller RL, Black DM, Durand DJ, Merrill JD, Eichenwald EC, Truog WE, Mammel MC, Steinhorn R, Ryan RM, Courtney SE, Horneman H, Ballard RA. Inhaled nitric oxide increases urinary nitric oxide metabolites and cyclic guanosine monophosphate in premature infants: relationship to pulmonary outcome. Am J Perinatol. 2015 Feb; 32(3):225-32. PMID: 24968129; PMCID: PMC5032843.
    48. Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia. 2014 Oct; 57(10):2057-65. PMID: 24908567; PMCID: PMC4344350.
    49. Szulc P, Blackwell T, Schousboe JT, Bauer DC, Cawthon P, Lane NE, Cummings SR, Orwoll ES, Black DM, Ensrud KE. High hip fracture risk in men with severe aortic calcification: MrOS study. J Bone Miner Res. 2014 Apr; 29(4):968-75. PMID: 23983224; PMCID: PMC3935989.
    50. Schousboe JT, Rosen HR, Vokes TJ, Cauley JA, Cummings SR, Nevitt M, Black DM, Orwoll ES, Kado DM, Ensrud KE. Prediction models of prevalent radiographic vertebral fractures among older women. J Clin Densitom. 2014 Jul-Sep; 17(3):378-85. PMID: 24582085; PMCID: PMC4119570.
    51. Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S. The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition. J Alzheimers Dis. 2014; 40(2):331-41. PMID: 24430001; PMCID: PMC4367860.
    52. Schousboe JT, Rosen HR, Vokes TJ, Cauley JA, Cummings SR, Nevitt MC, Black DM, Orwoll ES, Kado DM, Ensrud KE. Prediction models of prevalent radiographic vertebral fractures among older men. J Clin Densitom. 2014 Oct-Dec; 17(4):449-57. PMID: 24289883; PMCID: PMC4035457.
    53. Black DM, Schafer AL. The search for the optimal anabolic osteoporosis therapy. J Bone Miner Res. 2013 Nov; 28(11):2263-5. PMID: 24115189.
      View in: PubMed
    54. McNabb BL, Vittinghoff E, Schwartz AV, Eastell R, Bauer DC, Ensrud K, Rosenberg E, Santora A, Barrett-Connor E, Black DM. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013 Jun; 28(6):1319-27. PMID: 23408577.
      View in: PubMed
    55. Schwartz AV, Schafer AL, Grey A, Vittinghoff E, Palermo L, Lui LY, Wallace RB, Cummings SR, Black DM, Bauer DC, Reid IR. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res. 2013 Jun; 28(6):1348-54. PMID: 23322676.
      View in: PubMed
    56. Schwartz AV, Ewing SK, Porzig AM, McCulloch CE, Resnick HE, Hillier TA, Ensrud KE, Black DM, Nevitt MC, Cummings SR, Sellmeyer DE. Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women. Front Endocrinol (Lausanne). 2013; 4:62. PMID: 23755040; PMCID: PMC3667237.
    57. Napoli N, Schwartz AV, Palermo L, Jin JJ, Wustrack R, Cauley JA, Ensrud KE, Kelly M, Black DM. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab. 2013 Feb; 98(2):659-67. PMID: 23345099; PMCID: PMC3565107.
    58. Wolff EF, He Y, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Zhang H, Harman SM, Taylor HS. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertil Steril. 2013 Apr; 99(5):1385-91. PMID: 23312232.
      View in: PubMed
    59. Keller RL, Merrill JD, Black DM, Steinhorn RH, Eichenwald EC, Durand DJ, Ryan RM, Truog WE, Courtney SE, Ballard PL, Ballard RA. Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study. Pediatr Res. 2012 Dec; 72(6):613-9. PMID: 23037875; PMCID: PMC3548137.
    60. Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012 Aug; 27(8):1627-34. PMID: 22532515.
      View in: PubMed
    61. Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012 Oct; 97(10):3522-9. PMID: 22791766; PMCID: PMC3674294.
    62. Boonen S, Eastell R, Su G, Mesenbrink P, Cosman F, Cauley JA, Reid IR, Claessens F, Vanderschueren D, Lyles KW, Black DM. Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. J Bone Miner Res. 2012 Jul; 27(7):1487-93. PMID: 22431413; PMCID: PMC3636532.
    63. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012 Jun; 33(3):456-92. PMID: 22596255; PMCID: PMC3365859.
    64. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med. 2012 May 31; 366(22):2051-3. PMID: 22571169; PMCID: PMC4015798.
    65. Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, Dell R, Santora A, Chandler JM, Rix MM, Orwoll E. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012 May; 27(5):977-86. PMID: 22275107.
      View in: PubMed
    66. Napoli N, Jin J, Peters K, Wustrack R, Burch S, Chau A, Cauley J, Ensrud K, Kelly M, Black DM. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. J Clin Endocrinol Metab. 2012 Jul; 97(7):2414-22. PMID: 22547423; PMCID: PMC3387394.
    67. Black DM, Rosen CJ. Following the bone density trail: a clinical perspective. J Clin Endocrinol Metab. 2012 Apr; 97(4):1176-8. PMID: 22493309.
      View in: PubMed
    68. Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012 Apr; 27(4):808-16. PMID: 22190331; PMCID: PMC3510751.
    69. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012 Feb; 27(2):243-54. PMID: 22161728; PMCID: PMC3427916.
    70. Hillier TA, Lui LY, Kado DM, LeBlanc ES, Vesco KK, Bauer DC, Cauley JA, Ensrud KE, Black DM, Hochberg MC, Cummings SR. Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. J Bone Miner Res. 2012 Jan; 27(1):153-9. PMID: 22072593; PMCID: PMC3622730.
    71. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab. 2011 Dec; 96(12):E1982-9. PMID: 21994958; PMCID: PMC3232610.
    72. Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR. Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res. 2011 Oct; 26(10):2411-8. PMID: 21710615.
      View in: PubMed
    73. LeBlanc ES, Hillier TA, Pedula KL, Rizzo JH, Cawthon PM, Fink HA, Cauley JA, Bauer DC, Black DM, Cummings SR, Browner WS. Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med. 2011 Nov 14; 171(20):1831-7. PMID: 21949033; PMCID: PMC3576923.
    74. Hillier TA, Cauley JA, Rizzo JH, Pedula KL, Ensrud KE, Bauer DC, Lui LY, Vesco KK, Black DM, Donaldson MG, Leblanc ES, Cummings SR. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res. 2011 Aug; 26(8):1774-82. PMID: 21351144; PMCID: PMC3622725.
    75. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011 Jun 01; 305(21):2184-92. PMID: 21632482.
      View in: PubMed
    76. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 2011 May; 26(5):984-92. PMID: 21542001.
      View in: PubMed
    77. Li X, Kuo D, Schafer AL, Porzig A, Link TM, Black D, Schwartz AV. Quantification of vertebral bone marrow fat content using 3 Tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis. J Magn Reson Imaging. 2011 Apr; 33(4):974-9. PMID: 21448966; PMCID: PMC3072841.
    78. Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res. 2011 Apr; 26(4):683-8. PMID: 20939064; PMCID: PMC3179329.
    79. Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011 Jun; 96(6):1627-32. PMID: 21430030.
      View in: PubMed
    80. Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, Boonen S, Black D, Adachi JD. Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone. 2011 Jun 01; 48(6):1298-304. PMID: 21421092.
      View in: PubMed
    81. Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011 Mar; 124(3):199-205. PMID: 21396500; PMCID: PMC3107840.
    82. Katzman WB, Vittinghoff E, Ensrud K, Black DM, Kado DM. Increasing kyphosis predicts worsening mobility in older community-dwelling women: a prospective cohort study. J Am Geriatr Soc. 2011 Jan; 59(1):96-100. PMID: 21198460; PMCID: PMC3696343.
    83. Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res. 2011 Jan; 26(1):12-8. PMID: 20645415.
      View in: PubMed
    84. Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis. J Clin Densitom. 2011 Jan-Mar; 14(1):68-73. PMID: 21095149.
      View in: PubMed
    85. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010 Nov; 141(11):1365-70. PMID: 21037195.
      View in: PubMed
    86. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Dam TT, Curtis JR, Black DM, Bauer DC, Orwoll ES, Cummings SR. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010 Jul; 25(7):1506-11. PMID: 20200971; PMCID: PMC3153995.
    87. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010 May; 25(5):976-82. PMID: 20200926.
      View in: PubMed
    88. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010 May 13; 362(19):1761-71. PMID: 20335571.
      View in: PubMed
    89. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010 Feb; 58(2):292-9. PMID: 20070415; PMCID: PMC3660706.
    90. Hibbs AM, Black D, Palermo L, Cnaan A, Luan X, Truog WE, Walsh MC, Ballard RA. Accounting for multiple births in neonatal and perinatal trials: systematic review and case study. J Pediatr. 2010 Feb; 156(2):202-8. PMID: 19969305; PMCID: PMC2844328.
    91. Zupancic JA, Hibbs AM, Palermo L, Truog WE, Cnaan A, Black DM, Ballard PL, Wadlinger SR, Ballard RA. Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation. Pediatrics. 2009 Nov; 124(5):1325-32. PMID: 19841125.
      View in: PubMed
    92. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009 Sep; 24(9):1544-51. PMID: 19338427.
      View in: PubMed
    93. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009 Sep; 94(9):3215-25. PMID: 19567517.
      View in: PubMed
    94. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009 Jul; 94(7):2380-6. PMID: 19383780; PMCID: PMC2708944.
    95. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Black DM, Bauer DC, Cummings SR. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009 Apr; 24(4):675-80. PMID: 19049330; PMCID: PMC2659514.
    96. Prevrhal S, Krege JH, Chen P, Genant H, Black DM. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin. 2009 Apr; 25(4):921-8. PMID: 19250060.
      View in: PubMed
    97. Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009 Mar; 24(3):389-97. PMID: 18665786.
      View in: PubMed
    98. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008 Dec; 23(12):1974-82. PMID: 18684084; PMCID: PMC2686921.
    99. Cauley JA, Palermo L, Vogt M, Ensrud KE, Ewing S, Hochberg M, Nevitt MC, Black DM. Prevalent vertebral fractures in black women and white women. J Bone Miner Res. 2008 Sep; 23(9):1458-67. PMID: 18442309; PMCID: PMC2683160.
    100. Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan SL, Rosen C, Black D. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res. 2008 Sep; 23(9):1442-8. PMID: 18442311; PMCID: PMC2683159.
    101. Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, Ensrud KE, Nielson CM, Orwoll ES. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008 Aug; 23(8):1326-33. PMID: 18348697; PMCID: PMC2680175.
    102. Black DM, Boonen S, Delmas P, Lyles KW. Review of comparative effectiveness of treatments to prevent fractures. Ann Intern Med. 2008 Jun 03; 148(11):885-6; author reply 887. PMID: 18519940.
      View in: PubMed
    103. Truog WE, Martin RJ, Ballard RA, Black D, Cnaan A. Inhaled nitric oxide for preterm infants. Pediatrics. 2008 Jun; 121(6):1287-8; author reply 1288-9. PMID: 18519502.
      View in: PubMed
    104. Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008 Jun; 93(6):2166-72. PMID: 18349061; PMCID: PMC2435646.
    105. Prevrhal S, Shepherd JA, Faulkner KG, Gaither KW, Black DM, Lang TF. Comparison of DXA hip structural analysis with volumetric QCT. J Clin Densitom. 2008 Apr-Jun; 11(2):232-6. PMID: 18280192.
      View in: PubMed
    106. Ferrar L, Jiang G, Cawthon PM, San Valentin R, Fullman R, Lambert L, Cummings SR, Black DM, Orwoll E, Barrett-Connor E, Ensrud K, Fink HA, Eastell R. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J Bone Miner Res. 2007 Sep; 22(9):1434-41. PMID: 17563237.
      View in: PubMed
    107. Black DM, Rosen CJ. Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? Nat Clin Pract Rheumatol. 2007 Jul; 3(7):378-9. PMID: 17549088.
      View in: PubMed
    108. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 03; 356(18):1809-22. PMID: 17476007.
      View in: PubMed
    109. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007 May 03; 356(18):1895-6. PMID: 17476024.
      View in: PubMed
    110. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006 Dec 27; 296(24):2927-38. PMID: 17190893.
      View in: PubMed
    111. Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007 Mar; 92(3):942-7. PMID: 17164314; PMCID: PMC3746103.
    112. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006 Sep; 44(3):746-64. PMID: 16941705.
      View in: PubMed
    113. Jamal SA, Hamilton CJ, Black D, Cummings SR. The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. Trials. 2006 Apr 26; 7:10. PMID: 16640783; PMCID: PMC1471803.
    114. Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health. 2006 Jan-Feb; 9(1):54-8. PMID: 16441525.
      View in: PubMed
    115. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006 Feb; 21(2):292-9. PMID: 16418785.
      View in: PubMed
    116. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11; 353(6):555-65. PMID: 16093464.
      View in: PubMed
    117. Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab. 2005 Aug; 90(8):4566-72. PMID: 15899959.
      View in: PubMed
    118. Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, Black DM, Ensrud KE. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res. 2005 Jul; 20(7):1216-22. PMID: 15940375.
      View in: PubMed
    119. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005 Mar; 80(3):343-9. PMID: 15757015.
      View in: PubMed
    120. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005 May; 90(5):2787-93. PMID: 15728213.
      View in: PubMed
    121. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, Ross PD, Baran D. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005 Jun; 20(6):971-6. PMID: 15883637.
      View in: PubMed
    122. Antoniucci DM, Black DM, Sellmeyer DE. Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. Clin Chem. 2005 Jan; 51(1):258-61. PMID: 15613728.
      View in: PubMed
    123. Schwartz AV, Sellmeyer DE, Strotmeyer ES, Tylavsky FA, Feingold KR, Resnick HE, Shorr RI, Nevitt MC, Black DM, Cauley JA, Cummings SR, Harris TB. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res. 2005 Apr; 20(4):596-603. PMID: 15765178.
      View in: PubMed
    124. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res. 2005 Apr; 20(4):613-8. PMID: 15765180.
      View in: PubMed
    125. Jin H, Lu Y, Stone K, Black DM. Alternative tree-structured survival analysis based on variance of survival time. Med Decis Making. 2004 Nov-Dec; 24(6):670-80. PMID: 15534347.
      View in: PubMed
    126. Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res. 2005 Jan; 20(1):131-40. PMID: 15619679.
      View in: PubMed
    127. Jin H, Lu Y, Harris ST, Black DM, Stone K, Hochberg MC, Genant HK. Classification algorithms for hip fracture prediction based on recursive partitioning methods. Med Decis Making. 2004 Jul-Aug; 24(4):386-98. PMID: 15271277.
      View in: PubMed
    128. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004 Aug; 19(8):1250-8. PMID: 15231011.
      View in: PubMed
    129. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004 Aug; 19(8):1259-69. PMID: 15231012.
      View in: PubMed
    130. Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res. 2004 May; 19(5):764-72. PMID: 15068500.
      View in: PubMed
    131. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004 Jan 26; 164(2):146-52. PMID: 14744837.
      View in: PubMed
    132. Rosen CJ, Black DM, Greenspan SL. Vignettes in osteoporosis: a road map to successful therapeutics. J Bone Miner Res. 2004 Jan; 19(1):3-10. PMID: 14753730.
      View in: PubMed
    133. Cauley JA, Zmuda JM, Wisniewski SR, Krishnaswami S, Palermo L, Stone KL, Black DM, Nevitt MC. Bone mineral density and prevalent vertebral fractures in men and women. Osteoporos Int. 2004 Jan; 15(1):32-7. PMID: 14628107.
      View in: PubMed
    134. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25; 349(13):1207-15. PMID: 14500804.
      View in: PubMed
    135. Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst T, Secrest RJ, Pavo I. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone. 2003 Sep; 33(3):293-300. PMID: 13678769.
      View in: PubMed
    136. Varosy PD, Shlipak MG, Vittinghoff E, Black DM, Herrington D, Hulley SB, Browner WS. Fracture and the risk of coronary events in women with heart disease. Am J Med. 2003 Aug 15; 115(3):196-202. PMID: 12935826.
      View in: PubMed
    137. Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, Hochberg MC, McClung MR, Schnitzer TJ. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab. 2003 Aug; 88(8):3482-6. PMID: 12915621.
      View in: PubMed
    138. Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003; 21(5):305-14. PMID: 12627984.
      View in: PubMed
    139. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002 Oct 16; 288(15):1889-97. PMID: 12377088.
      View in: PubMed
    140. Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry: clinical applications. JAMA. 2002 Oct 16; 288(15):1898-900. PMID: 12377089.
      View in: PubMed
    141. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ, Margolis KL, Cauley JA, Nevitt MC, Black DM, Cummings SR. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002 Oct; 25(10):1749-54. PMID: 12351472.
      View in: PubMed
    142. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 Aug; 87(8):3609-17. PMID: 12161484.
      View in: PubMed
    143. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002 Aug; 23(4):508-16. PMID: 12202465.
      View in: PubMed
    144. Black D, Wagman RB. Identifying fracture risk in postmenopausal women. JAMA. 2002 Mar 06; 287(9):1109; author reply 1110. PMID: 11879095.
      View in: PubMed
    145. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc. 2002 Mar; 50(3):409-15. PMID: 11943033.
      View in: PubMed
    146. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002 Mar; 112(4):281-9. PMID: 11893367.
      View in: PubMed
    147. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 Jan; 17(1):1-10. PMID: 11771654.
      View in: PubMed